newsfilter
← Latest News
GlobeNewswire·

Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®

94% of participants maintained seroresponse five years after a single vaccinationComparable antibody persistence observed in older (65+) and younger adultsData further reinforce IXCHIQ®'s differentiated profile with